BioNTech SE American Depositary Share (BNTX)
Stock · NASDAQ · Health Care
$87.69as of 10/16/2026
Price chart
Active signals
Support Reject75.1%BOLL Breakdown70.2%200 SMA Touch50.0%
High Beta21.0%
Revenue-Price Divergence (6M)13.0%Resistance level
$90.86
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
BNTX Signal Track Record
How signals performed across all stocks →What BNTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | -0.9% | 49% | September 14, 2026 |
| Bollinger Band BreakdownActive now | 26 | -3.4% | 46% | October 8, 2026 |
| Bollinger Band Breakout | 26 | -5.4% | 23% | August 19, 2026 |
| 200-Day Moving Average TouchActive now | 18 | -6.9% | 17% | October 9, 2026 |
| Any 20-session window (baseline) | -1.2% | 44% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BNTX
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 7,807
- Website
- www.biontech.com/
Fundamentals
- 1-day range
- $87.36$90.14
- Market cap
- $22.91B
- P/E (trailing)
- —
- P/E (forward)
- -15.65
- EPS (trailing)
- $-6.71
- Dividend yield
- —
- Beta
- 1.33
- Avg. volume
- 1.21M
- Ex-dividend date
- June 2, 2022
- Dividend pay date
- June 17, 2022
52-week range
$79.52$124
Next earnings: November 3, 2026 · EPS estimate $0.76confirmed
Forecasts
20 analyst ratings
Buy 78%
Hold 22%
Sell 0%
1-year price forecast
High
$144.57
+64.9%
Median
$125.14
+42.7%
Low
$76.3
-13.0%
BioNTech SE American Depositary Share Competitors
Chosen by industry and closest market cap.
- BNTXBioNTech SE American Depositary Share$87.71▼ 2.76%Market cap $22.91BP/E —$79.52$124
- MRNAModerna Inc. Common Stock$218.01▼ 7.82%Market cap $21.50BP/E —$22.28$227.46
- NBIXNeurocrine Biosciences Inc. Common Stock$135.71▼ 0.91%Market cap $16.25BP/E 19.57$122.14$186.12
- BIIBBiogen Inc. Common Stock$232.65▼ 1.15%Market cap $30.48BP/E 42.27$138$238.24
- EXELExelixis Inc. Common Stock$62.23▼ 0.95%Market cap $13.12BP/E 17.49$33.76$61.66
- HALOHalozyme Therapeutics Inc. Common Stock$121.84▲ 0.27%Market cap $10.17BP/E 32.51$61.23$119.21
- KRYSKrystal Biotech Inc. Common Stock$316.58▼ 4.07%Market cap $9.55BP/E 40.85$181.44$382.54
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BNTX BioNTech SE American Depositary Share | $22.91B | — | $87.71 | ▼ 2.76% | $79.52$124 |
| MRNA Moderna Inc. Common Stock | $21.50B | — | $218.01 | ▼ 7.82% | $22.28$227.46 |
| NBIX Neurocrine Biosciences Inc. Common Stock | $16.25B | 19.57 | $135.71 | ▼ 0.91% | $122.14$186.12 |
| BIIB Biogen Inc. Common Stock | $30.48B | 42.27 | $232.65 | ▼ 1.15% | $138$238.24 |
| EXEL Exelixis Inc. Common Stock | $13.12B | 17.49 | $62.23 | ▼ 0.95% | $33.76$61.66 |
| HALO Halozyme Therapeutics Inc. Common Stock | $10.17B | 32.51 | $121.84 | ▲ 0.27% | $61.23$119.21 |
| KRYS Krystal Biotech Inc. Common Stock | $9.55B | 40.85 | $316.58 | ▼ 4.07% | $181.44$382.54 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $132benzinga · 10/14/2026
- Why Did BioNTech (BNTX) Move Today?Yahoo · 10/10/2026
- Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks UpYahoo · 10/9/2026
- A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock RallyBenzinga · 10/9/2026
- Reported Earlier: 'Cancer Vaccines Are the N.I.H's Next Big Bet' - The New York TimesBenzinga · 10/9/2026
- Is BioNTech (NasdaqGS:BNTX) Overvalued As Sales Face A Reset?Yahoo · 10/7/2026
- Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $114Benzinga · 10/7/2026
- Moderna Is Up 545% in 2026: Take Profits Now, or Keep Buying?Yahoo · 10/6/2026
- Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer SlipsYahoo · 10/5/2026
Insider Activity
Insider Actions →Acquired
0
Disposed
487.2K
- Sahin Ugur · October 9, 2026 · Sale36.2K @ $95.37
- Sahin Ugur · October 8, 2026 · Sale27.0K @ $92.31
- Sahin Ugur · October 7, 2026 · Sale24.0K @ $95.86
- Sahin Ugur · October 6, 2026 · Sale21.0K @ $96.81
- Sahin Ugur · October 5, 2026 · Sale72.0K @ $97.23
- Sahin Ugur · October 2, 2026 · Sale17.0K @ $96.72
- Sahin Ugur · October 1, 2026 · Sale17.0K @ $97.46
- Sahin Ugur · September 28, 2026 · Sale34.0K @ $98.47
- Sahin Ugur · September 25, 2026 · Sale27.0K @ $98.69
- Sahin Ugur · September 24, 2026 · Sale39.0K @ $98.99
- Sahin Ugur · September 23, 2026 · Sale30.0K @ $99.4
- Sahin Ugur · September 22, 2026 · Sale46.0K @ $100.72
- Sahin Ugur · September 21, 2026 · Sale33.0K @ $97.81
- Sahin Ugur · September 18, 2026 · Sale30.0K @ $96.22
- Sahin Ugur · September 17, 2026 · Sale34.0K @ $98.6
Institutional Ownership
March 31, 2026
- Total shares held
- 49.63M
- Total value held
- $3.81B
- Institutional holders
- 272
Top holders this quarter
- Unknown5.86M
- Unknown5.71M
- Unknown3.79M
- Unknown3.68M
- Unknown3.68M
- Unknown1.66M
- Unknown1.65M
- Unknown1.54M
- Unknown1.51M
- Unknown903.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BioNTech shares slip after cancer trial misses PFS endpoint
BioNTech's shares fell about 7% after a late‑stage mRNA cancer vaccine trial did not meet its primary progression‑free survival goal. The miss has prompted analysts to reassess the company's oncology pipeline and contributed to a broader pullback in the stock. Canaccord Genuity kept its rating but lowered its price target to $132, reflecting the recent results. The stock is trading near a support level around $90.86 and its RSI is in the lower‑mid range.
BioNTech shares slip after cancer trial misses PFS endpoint. BioNTech's shares fell about 7% after a late‑stage mRNA cancer vaccine trial did not meet its primary progression‑free survival goal. The miss has prompted analysts to reassess the company's oncology pipeline and contributed to a broader pullback in the stock. Canaccord Genuity kept its rating but lowered its price target to $132, reflecting the recent results. The stock is trading near a support level around $90.86 and its RSI is in the lower‑mid range.